Arda Ersan, Cakiroglu Basri, Cetin Gizem, Yuksel Ilkan
Urology, Trakya University Medical Faculty.
Urology, Hisar Intercontinental Hospital.
Cureus. 2017 Nov 9;9(11):e1833. doi: 10.7759/cureus.1833.
Testicular cancer represents approximately 1% of all cancers diagnosed in males. The prevalence of bilateral testicular germ cell tumor cases varies from 1% to 5%. Intratubular germ cell neoplasia (ITGCN) is a precursor for almost all testicular germ cell tumors (TGCT) and is one of the highest risks of developing contralateral testicular cancer. The radical orchiectomy is still preferred for the treatment of testicular cancer. However, in some cases like solitary testis, bilateral cancer or if the tumor size is under 30% percent of the testicular extent, organ-sparing surgery can be an option. There are just a few published reports of metachronous contralateral testicular cancer, developed after orchiectomy with the histopathology of the intratubular germ cell neoplasia.
睾丸癌约占男性确诊癌症总数的1%。双侧睾丸生殖细胞肿瘤病例的患病率在1%至5%之间。管内生殖细胞瘤变（ITGCN）几乎是所有睾丸生殖细胞肿瘤（TGCT）的前身，也是发生对侧睾丸癌的最高风险之一。根治性睾丸切除术仍是治疗睾丸癌的首选方法。然而，在一些情况下，如单睾、双侧癌症或肿瘤大小占睾丸范围不到30%时，保留器官手术也可作为一种选择。关于睾丸切除术后发生异时性对侧睾丸癌且伴有管内生殖细胞瘤变组织病理学特征的报道仅有几例。
